1 / 1

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market

Market Size of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma in the 6MM is anticipated to be USD 2796.2 Million in 2030.<br>Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the United States.<br>Advancements in technology, Increased collaborations & acquisitions and Competition among biotech and pharma giants are some of the factors expected to drive the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market in the coming years.<br>The key players in the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market include Novartis, Kite Pharma, Gilead Sciences, Celgene Corporation and others.<br>

DelveInsight
Download Presentation

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related